JP7837513B2 - セレノネインを含む、ｃｏｖｉｄ１９治療又は予防薬 - Google Patents

セレノネインを含む、ｃｏｖｉｄ１９治療又は予防薬

Info

Publication number
JP7837513B2
JP7837513B2 JP2023500976A JP2023500976A JP7837513B2 JP 7837513 B2 JP7837513 B2 JP 7837513B2 JP 2023500976 A JP2023500976 A JP 2023500976A JP 2023500976 A JP2023500976 A JP 2023500976A JP 7837513 B2 JP7837513 B2 JP 7837513B2
Authority
JP
Japan
Prior art keywords
protease
selenonein
pro
tuna
papain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023500976A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022177029A5 (https=
JPWO2022177029A1 (https=
Inventor
紀行 鈴木
康光 小椋
泰典 福本
惠一 市川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kikkoman Corp
Chiba University NUC
Original Assignee
Kikkoman Corp
Chiba University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kikkoman Corp, Chiba University NUC filed Critical Kikkoman Corp
Publication of JPWO2022177029A1 publication Critical patent/JPWO2022177029A1/ja
Publication of JPWO2022177029A5 publication Critical patent/JPWO2022177029A5/ja
Application granted granted Critical
Publication of JP7837513B2 publication Critical patent/JP7837513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023500976A 2021-02-22 2022-02-22 セレノネインを含む、ｃｏｖｉｄ１９治療又は予防薬 Active JP7837513B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2021026585 2021-02-22
JP2021026585 2021-02-22
JP2021106076 2021-06-25
JP2021106076 2021-06-25
JP2021165803 2021-10-07
JP2021165803 2021-10-07
PCT/JP2022/007397 WO2022177029A1 (ja) 2021-02-22 2022-02-22 セレノネインを含む、ｃｏｖｉｄ１９治療又は予防薬

Publications (3)

Publication Number Publication Date
JPWO2022177029A1 JPWO2022177029A1 (https=) 2022-08-25
JPWO2022177029A5 JPWO2022177029A5 (https=) 2024-12-24
JP7837513B2 true JP7837513B2 (ja) 2026-03-31

Family

ID=82931986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500976A Active JP7837513B2 (ja) 2021-02-22 2022-02-22 セレノネインを含む、ｃｏｖｉｄ１９治療又は予防薬

Country Status (4)

Country Link
US (1) US20250352517A1 (https=)
JP (1) JP7837513B2 (https=)
TW (1) TWI911391B (https=)
WO (1) WO2022177029A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115737675B (zh) * 2022-11-28 2024-03-08 安徽农业大学 氧化型硒代硫酸钠的制备及其在治疗冠状病毒感染中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504355B2 (en) * 2018-03-05 2022-11-22 Mironova Innovations, Llc Ergothioneine compositions and methods for maintaining and/or increasing vitamin C levels in cells and organisms

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN L.R. et al.，Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors，Bioorganic and Medicinal Chemistry Letters，2005年，Vol.15，pp.3058-3062
PARK J.Y.et al.，Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases，Bioorganic and Medicinal Chemistry，Vol.20，2012年，pp.5928-5935
SINGH B.G.et al.，In silico investigation on the binding of organoselenium compounds with target proteins of SARS-CoV-，ChemRxiv，2020年07月02日，[retrieved on 2021-04-30]. Retrieved from Internet, doi:10.26434/chemrxiv.12594134
山下倫明，魚類に豊富に含まれる「セレン」新型コロナウイルスにも有効，養殖ビジネス，2020年10月01日，Vol.57, No.10，pp.62-67

Also Published As

Publication number Publication date
TW202302093A (zh) 2023-01-16
TWI911391B (zh) 2026-01-11
US20250352517A1 (en) 2025-11-20
WO2022177029A1 (ja) 2022-08-25
JPWO2022177029A1 (https=) 2022-08-25

Similar Documents

Publication Publication Date Title
KR101771867B1 (ko) 디펩티딜 펩티다아제 ⅳ (dppⅳ) 저해 펩티드 화합물, 그것을 함유하는 조성물, 및 그 제조 방법
US20150232510A1 (en) Dipeptidyl peptidase-iv inhibitor
JP7837513B2 (ja) セレノネインを含む、ｃｏｖｉｄ１９治療又は予防薬
WO2009035169A1 (ja) 血圧上昇抑制作用を有するぺプチド
Subash et al. In vivo and in silico investigations on the efficacy of albendazole against Enterocytozoon hepatopenaei (EHP) infecting Penaeus vannamei
JPWO2013133032A1 (ja) ジペプチジルペプチダーゼ−ｉｖ阻害剤
Cao et al. A novel angiotensin I-converting enzyme (ACE) inhibitory peptide from Wuyi rock tea residue: Preparation, identification, and its potential molecular mechanism
US20050037953A1 (en) Inhibitors of plasmepsins
Kumar et al. Recent development in identification of potential novel therapeutic targets against trypanosomatids
JP5220415B2 (ja) 老人性貧血を防止又は治療するためのアミノ酸組成物
JP6153736B2 (ja) 癌細胞増殖抑制剤並びに健康食品
Azam et al. Targeting Amoebiasis: status and developments
JP2008214232A (ja) コラーゲン合成促進剤
CN112294793B (zh) 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用
KR20180014360A (ko) 만성 염증성 장 질환 치료용 또는 장 기능 개선용 조성물
KR101284838B1 (ko) 소목 추출물을 함유하는 혈관질환의 치료 또는 예방용 조성물
JP7787491B2 (ja) コロナウイルスメインプロテアーゼ阻害剤、コロナウイルス予防剤、コロナウイルス治療剤及びコロナウイルス予防食品
KR20240142972A (ko) 제2형 중증 급성 호흡기 증후군 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물 및 건강기능식품
CA2922396C (en) N-acetyl l-cysteine chelates and methods for making and using the same
KR102361965B1 (ko) 락토바실러스 플란타룸 균주 또는 이의 배양액을 유효성분으로 함유하는 항바이러스 조성물
Ahmed et al. After one year of the COVID-19 pandemic and hundreds of suggested drugs, will cathepsin L inhibitors be the solution?
JP2007223902A (ja) 新規イソクロマン化合物とその抗がん剤等への利用
CN109790523A (zh) 组合物及其用途
da Silva Medeiros et al. Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity
KR20240014381A (ko) 유스카픽 에시드를 포함하는 근 기능 개선 또는 근육 질환 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260310

R150 Certificate of patent or registration of utility model

Ref document number: 7837513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150